Lactated Ringer Versus Albumin in Early Sepsis Therapy (RASP)
Septic Shock, Severe Sepsis
About this trial
This is an interventional treatment trial for Septic Shock focused on measuring Septic shock, Sepsis, Albumin, Lactated Ringer
Eligibility Criteria
Inclusion Criteria:
- Age equal or higher than 18 years-old
- Severe sepsis or septic shock into 6 hours of evolution
- Written informed consent
Exclusion Criteria:
- Shock from other causes
- Adverse reactions to human albumin
- Previous fluid resuscitation during current disease
- Previous use of albumin in the last 72 hours
- Religion objection
- Enrollment in another study
- Traumatic brain injury
- Hepatic cirrhosis
- End stage renal disease
- Plasmapheresis
- End of life patients
Sites / Locations
- Cancer Institute of Sao Paulo, School of Medicine, University of Sao Paulo
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Active Comparator
Lactated Ringer
Albumin
Patients randomized for this group will receive 500 ml of lactated Ringer solution in early phase of sepsis or septic shock (less than six hour from sepsis onset) if mean arterial pressure was under 65mmHg, or blood lactate concentration higher than 4 mmol/L or base excess under - 4mmol/L until the target of central venous pressure of 8 mmHg or higher or recovery of hypotension.
Patients randomized for Albumin group will receive 500 ml of 4% Albumin solution in early phase of sepsis (less than six hour from sepsis onset) if mean arterial pressure was under 65mmHg or blood lactate concentration higher than 4 mmol/L or base excess under - 4mmol/L until the target of central venous pressure of 8 mmHg or higher or recovery of hypotension.